Risk of hyperglycaemia w/ inadequate dosage or discontinuation of treatment, especially in type 1 DM. Risk of hypoglycaemia w/ excessive insulin dose, omitted meal or unplanned, strenuous physical exercise. Change in usual warning symptoms of hypoglycaemia in patients w/ greatly improved blood glucose control eg, by intensified therapy, & w/ longstanding diabetes. Change in strength, brand (manufacturer), type, origin (animal, human insulin or human insulin analogue) &/or method of manufacture of insulin. Patients w/ concomitant illness, especially infections & feverish conditions; concomitant diseases in the kidney, liver or affecting the adrenal, pituitary, or thyroid gland; patients travelling between different time zones. Rotate inj site continuously to reduce or prevent inj site reactions. Cases of CHF in combination w/ pioglitazone. Insulin administration may cause insulin antibodies to form, adjustment of insulin dose is necessary in order to correct a tendency to hyper- or hypoglycaemia. May impair ability to drive & use machines. Pregnancy & lactation.
Sign Out
